12-Oxocalanolide A
12-Oxocalanolide A is an inhibitor of HIV-1 reverse transcriptase (RT) and exhibits activity against a variety of viruse selected for resistance to other HIV-1 nonnucleoside RT inhibitors.
Inquire / Order:
manager@chemfaces.com
Technical Inquiries:
service@chemfaces.com
Tel:
+86-27-84237783
Fax:
+86-27-84254680
Address:
1 Building, No. 83, CheCheng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, PRC
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to
24 months(2-8C).
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com
The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
J Integr Plant Biol.2023, 13564.
Curr Issues Mol Biol.2023, 45(2):1587-1600.
Molecules.2020, 25(3):734
Chem Biol Interact.2019, 315:108910
Int J Med Sci.2020, 17(5):626-631
Food Addit Contam Part A.2021, 38(12):1985-1994.
Int J Mol Sci.2020, 21(9):3239.
Arch Toxicol.2017, 91(10):3225-3245
Allergol Immunopathol (Madr).2022, 1;50(4):23-30.
Pak J Pharm Sci.2019, 32(6)
Related and Featured Products
Bioorg Med Chem Lett. 1998 Aug 18;8(16):2179-84
In vitro anti-human immunodeficiency virus (HIV) activity of the chromanone derivative, 12-oxocalanolide A, a novel NNRTI.[Pubmed:
9873509]
METHODS AND RESULTS:
The three chromanone derivatives, (+)-, (-)-, and (+/-)-12-Oxocalanolide A (2), were evaluated for in vitro antiviral activities against HIV and simian immunodeficiency virus (SIV).
CONCLUSIONS:
The compounds were determined to be inhibitors of HIV-1 reverse transcriptase (RT) and exhibited activity against a variety of viruses selected for resistance to other HIV-1 nonnucleoside RT inhibitors. They are the first reported calanolide analogues capable of inhibiting SIV.
J Chromatogr B Biomed Sci Appl. 2000 Jun 9;742(2):267-75.
Quantification of (+)-calanolide A, a novel and naturally occurring anti-HIV agent, by high-performance liquid chromatography in plasma from rat, dog and human.[Pubmed:
10901131]
METHODS AND RESULTS:
A HPLC method was validated for quantification of (+)-calanolide A (1), a novel anti-HIV agent, in rat, dog and human plasma. The synthetic intermediate (+/-)-12-Oxocalanolide A (2) was found to be a suitable internal standard. Compounds were extracted from plasma using a solid-phase C(18) cartridge and quantified over the assay range of 12.5 to 800 ng/ml. The method was utilized to determine (+)-calanolide A pharmacokinetics in rats, dogs and humans. This is the first report of a validated HPLC assay for determination of (+)-calanolide A concentrations in rat and dog plasma as well as human plasma obtained from clinical trials.
CONCLUSIONS:
There was no evidence of in vivo epimerization of (+)-calanolide A to its inactive epimer (+)-calanolide B (3).
